89 results about "Receptor interaction" patented technology

The invention belongs to the field of bioinformatics, and relates to an improved integrated deep learning cell communication ligand-receptor interaction prediction method. The method comprises the following steps: firstly, carrying out extraction and dimensionality reduction on biological sequence features of a ligand and a receptor, and constructing multi-modal feature input; secondly, constructing an improved deep neural network branch, introducing a batch normalization layer and a Leaky ReLU activation function, solving the problems of gradient disappearance and neuronal necrosis, and improving regularization strength to prevent overfitting; meanwhile, an enhanced heterogeneous graph auto-encoder branch is constructed, the graph embedding dimension is remarkably expanded to improve the feature capacity, and full convergence of the model is ensured by increasing training rounds; thirdly, fusing the improved deep network with the prediction probability of a heterogeneous graph auto-encoder by adopting a weighted integration strategy; and finally, outputting a potential interaction relationship based on the fusion probability. By optimizing the architecture and the strategy, the prediction accuracy and robustness are remarkably improved, and a reliable tool is provided for analyzing a complex cell communication network.

The present invention relates to tetrahydrobenzo-isoquinoline sulfonamides derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular disorders caused by the interaction of IgE with the FIERI receptor.

The invention relates to RIP1 inhibiting compounds and methods of making and using the same. In particular, disclosed herein are kinase inhibitory compounds, such as receptor interacting protein-1 (RIP1) kinase inhibitor compounds, and pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions and / or combinations may be used to treat or prevent kinase-related diseases or disorders, particularly RIP1-related diseases or disorders.

A dynamic antimicrobial hydrogel based on natural receptor-ligand recognition, and a preparation method and use thereof are provided. A ligand vancomycin and a receptor AA-based material each are first modified with a modification material, and then a photoinitiator is added to prepare a hydrogel material under irradiation of ultraviolet (UV) light. In the hydrogel, a three-dimensional (3D) network structure is formed through crosslinking. After undergoing a fracture under an external pressure, the hydrogel can rapidly heal itself through crosslinking due to a ligand-receptor interaction and a multi-hydrogen-bond interaction, which bio-mimicks a natural ligand-receptor interaction to realize the dynamics of the hydrogel material. The high antiomicrobial activity of vancomycin imparts the functionality of the hydrogel material; and the physiologically-derived monomer improves the biocompatibility and reduces the biological toxicity.

The present invention relates to a polymer conjugate comprising a ULA polymer a) and one or more polypeptides b), wherein the polypeptides are conjugated to the ULA polymer, and the conjugate is coated on the surface of a device for culturing cells. The peptides can interact with receptors on the surface of the cells, while the polymer prevents non-specific binding of the cells to the surface of the device.

This invention relates to a novel use of IL-1β-ligand / IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1b ligand-IL-1 receptor interaction, IL-1b antibodies or IL-1 receptor antibodies, e.g. IL-1b binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1b binding compounds or IL-1 receptor binding compounds, and / or RNA compounds decreasing either IL-1b ligands or IL-1 receptor protein levels, in the treatment and / or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and / or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.

Provided are a compound as a receptor-interacting protein (RIP) inhibitor, a preparation method therefor, and a use thereof, relating to the field of chemical medicines. The compound is a compound as represented by formula (I), or a salt thereof, or a stereoisomer thereof, or a solvate thereof, or a prodrug thereof. The compound has good inhibitory activity on humanized RIP1 kinase, and can be used for preparing drugs for resisting inflammation, resisting tumors and the like.

The invention discloses a double-gene engineered mesenchymal stem cell and application thereof, and relates to the technical field of biological medicines. According to the double-gene engineered mesenchymal stem cell provided by the invention, CXCR4 and TNFSF14 proteins are co-expressed by the mesenchymal stem cell, and the mesenchymal stem cell shows enhanced tumor tropism and immune-mediated anti-tumor activity. Specifically, based on the principles that CXCR4 can enhance the active homing ability of mesenchymal stem cells to gastric cancer lesions expressing ligands SDF-1 (SDF-1 / CXCL12) of the mesenchymal stem cells, TNFSF14 (LIGHT can interact with HVEM and LT betaR receptors to promote activation of T cells and NK cells and the like, the mesenchymal stem cells co-expressing CXCR4 and LIGHT overcome the defects that natural MSCs are insufficient in targeting ability and weak in immune activation ability; the excellent anti-tumor effect is realized.

The present invention relates to compounds of formula (I), pharmaceutical compositions containing them, processes for their preparation, and their use as receptor interacting protein kinase 1 (RIPK1) inhibitors. The invention also relates to application of the compound or the composition containing the compound to treatment or prevention of related diseases or symptoms mediated by RIPK1. # imgabs0 #

The application discloses double-gene engineered mesenchymal stem cells and application thereof, relates to the technical field of biological medicine. The double-gene engineered mesenchymal stem cells provided by the application co-express CXCR4 and TNFSF14 proteins, exhibit enhanced tumor tropism and immune-mediated anti-tumor activity. Specifically, based on the principle that CXCR4 can enhance the active homing ability of mesenchymal stem cells to gastric cancer lesions expressing its ligand SDF-1 (SDF-1 / CXCL12), and TNFSF14 (LIGHT) can interact with HVEM and LTbetaR receptors to promote the activation of T cells and NK cells, the mesenchymal stem cells co-expressing CXCR4 and LIGHT overcome the defects of insufficient targeting of natural MSCs and weak immune activation ability, and have excellent anti-tumor effect.

The invention provides a granulocyte-macrophage colony stimulating factor antibody and application thereof, and belongs to the technical field of biological medicine. A granulocyte-macrophage colony stimulating factor (GM-CSF) antibody or fragment has high affinity, can effectively block GM-CSF / GM-CSF receptor interaction, and has low immunogenicity. The GM-CSF antibody or fragment can be used for preventing and / or treating diseases caused by human GM-CSF or detecting human GM-CSF protein or diagnosing related diseases caused by the human GM-CSF protein.

Disclosed herein are methods, compositions, systems, and kits related to functional testing of polypeptide-target interactions, such as antigen / immune receptor interactions, in a single-cell format.

The present disclosure provides compounds, including piperazine heterocyclic amide urea compounds (including the corresponding sulfonamides), that inhibit cell necrosis and / or human receptor-interacting protein 1 kinase (RIP1), and pharmaceutically acceptable salts, hydrates, and stereoisomers thereof. The compounds of the present invention are used in pharmaceutical compositions and methods of use and manufacturing, including treating a person in need thereof with an effective amount of a compound or composition of the present invention and detecting a resulting improvement in the person's health or condition.

The present invention pertains to the treatment of diseases associated with a dysregulated immune response such as auto immune disorders, inflammatory diseases or pathological immune responses as adverse effects of medical treatments. In particular the invention provides a combined use of inhibitors of Receptor-interacting serine / threonine-protein kinase (RIPK1) and inhibitors of Inhibitor of κB (IκB) Kinase (IKK) in subjects suffering from such disorders. The invention provides such inhibitory compounds and their combinations for use in medical applications, as well as pharmaceutical compositions comprising the compounds of the invention.

Antibodies that target VZV glycoprotein E (gE) bind to recombinant gE with high affinity, bind to gE on the surface of VZV infected cells, interact with immune system effectors (e.g., Fc receptors), mediate antibody-dependent cellular cytotoxicity (ADCC) as well as Antibody Dependent Cellular Phagocytosis (ADCP), and prevent VZV infection of cells.

This invention provides material compositions and / or methods suitable for the prevention and / or treatment of protein depletion (protein deficiency), comprising material compositions that preserve the natural function of peptides / proteins while limiting and / or preventing the formation and / or aggregation of said peptides / proteins into amyloid protein. It also provides material compositions and formulations for enhancing peptide / protein solubility, stability, cycle time, receptor interaction, brain permeability, CSF half-life, and promoting peptide / protein synthesis and purification.

The invention discloses a traditional Chinese and western medicine disease and syndrome combined hepatic ischemia-reperfusion injury ligand and receptor interaction communication network construction method, system and device, a medium and a product, and relates to the field of medicine. Traditional Chinese medicinal materials related to occurrence and development of the hepatic ischemia-reperfusion injury are identified from Chinese literatures and Chinese patents; constructing a traditional Chinese medicine target group based on traditional Chinese medicines; keywords are set based on pathological knowledge of western medicine, and biomarkers or target protein groups related to occurrence and development of hepatic ischemia-reperfusion injury are identified from different literatures; constructing a disease target group based on the biomarker or the target protein group; the traditional Chinese medicine target group and the disease target group form a liver transplantation HIRI target network; and performing network topology comparison on the traditional Chinese medicine target group and the disease target group to determine an optimal traditional Chinese medicine. According to the application, the advantages of combination of traditional Chinese medicine and western medicine are exerted, and the corresponding traditional Chinese medicinal materials are determined by constructing the liver transplantation HIRI target network.

The invention discloses an application of sodium bicarbonate in preparation of a tumor immune drug enhancer. The molecular formula of the sodium bicarbonate is NaHCO3. Tumor necrosis factor alpha (TNF-alpha) is used as an anti-tumor drug to treat tumors, however, the anti-tumor efficacy of the TNF-alpha is unpredictable. It is proved that TNF-alpha activates a nuclear factor kappa B (nuclear factor kappa-light-chain-energy active B cells, NF-kappa B) signal channel, inflammatory response is enhanced, tumor cell growth is promoted, and the TNF-alpha can activate a nuclear factor kappa B (nuclear factor kappa-light-chain-energy active B cells (NF-kappa B) signal channel. Under the action of sodium bicarbonate, a TNF-alpha mediated NF-kappa B signal channel is inhibited, a TNF-alpha mediated receptor-interacting serine / threonine-protein kinase 1 (RIPK1) dependent Necroptosis signal channel is activated, and the death of tumor cells is caused, so that the TNF-alpha mediated receptor-interacting serine / threonine-protein kinase 1 (RIPK1) depends on the TNF-alpha mediated receptor-interacting serine / threonine-protein kinase 1 (RIPK1) and the TNF-alpha mediated receptor-interacting serine / threonine-protein kinase 1 (RIPK1). The prepared medicine contains a medicine excipient or a carrier allowed by a preparation. The invention develops new application of sodium bicarbonate in preparation of medicines for treating tumors. And the medicine is non-toxic to a human body after being administrated in a tumor body. Sodium bicarbonate can be used for preparing a reinforcing agent of TNF-alpha.

A computational framework for high-throughput mapping, validating, and predicting receptor sequence interactions is described. A method includes pre-processing sequence data, adjusting data for noise, generating intermediate strength of interaction data, aggregating the intermediate strength of interaction data based on dextramer clustering and based on TCR clustering, and generating final relative strength of interaction data that identifies reliable TCR-pMHC binding events.

The present invention discloses a compound with RIPK1 inhibitory activity, a preparation method, and uses thereof. The compound structure is shown in Formula I, and the definitions of the substituents are as described in the specification and claims. The compound of the present invention can be used to treat inflammatory diseases, ischemic diseases, neurodegenerative diseases, tumors, and other conditions and diseases associated with receptor-interacting protein kinase 1.

The invention provides an intercellular communication dynamic analysis method and system based on a graph reaction diffusion model, and relates to the field of biological information analys.The method comprises the steps that spatial transcriptome data to be analyzed is obtained, and meanwhile a ligand-receptor reaction database is introduced; constructing a reaction-diffusion partial differential equation set by utilizing a Fick law and a mass action law based on the ligand-receptor reaction database; a graph signal processing method is introduced, cells in space transcriptome data are defined as nodes, a space graph is constructed based on the space neighborhood relation of the cells, a graph Laplacian matrix of the space graph is calculated, a reaction-diffusion partial differential equation set is converted into a graph signal form, numerical solution is carried out, and the response-diffusion partial differential equation set is obtained. Simulating a spatio-temporal evolution process of ligand-receptor interaction to obtain cell-cell communication information depicted by a ligand-receptor reaction intensity matrix; accurate inference of cell-cell communication is realized under various space omics platforms, and the method has relatively high stability, generalizability and biological interpretability.

This invention discloses an epitope peptide of the key SRCR5 domain of porcine reproductive and respiratory syndrome virus (PRRSV) CD163, an epitope peptide vaccine, and its applications. The epitope vaccine of this invention exhibits good safety, without safety issues such as virulence reversion, viremia, or recombination with other PRRSV strains. It also demonstrates good immunogenicity; 14 days after secondary immunization, it can induce pigs to produce specific antibodies against the CD163 SRCR5-FP14 epitope with a maximum agglutination titer of 1:16. Immunized pigs can resist challenge from the highly pathogenic PRRSV JAX1 strain. Since all PRRSV subtypes rely on interaction with the CD163 receptor to infect susceptible host cells, and the CD163 molecule is conserved, the epitope vaccine blocking PRRSV infection also provides broad-spectrum protection against multiple subtypes without affecting pig production performance. This novel epitope vaccine has broad potential applications in PRRS prevention and control.

This application relates to targeting peptides and engineering AAV capsids. In some embodiments, the targeting peptides and engineered AAV capsids are capable of interacting with LDLR receptor to mediate delivery to a cell or tissue.

A therapeutic composition is described including a selective soluble TNF-neutralizing bioconjugate for treating TNF-mediated inflammatory disorders. The bioconjugate includes a dominant-negative TNF (DN-TNF) mutein, which contains one or more amino acid substitutions in the TNF receptor interaction domain, trimer interface domain, or both, to reduce receptor binding while enhancing heterotrimer formation with wild-type TNF, thereby neutralizing soluble TNF. The DN-TNF mutein is covalently conjugated to a biocompatible stealth polymer via a hydrolyzed maleimide linker, preventing retro-Michael reaction and polymer dissociation. The composition is formulated as an injectable buffered aqueous solution for subcutaneous, intramuscular, intravitreal, or intravenous administration. Also disclosed are methods for stabilizing the bioconjugate through controlled hydrolysis of the maleimide linker and methods for treating TNF-mediated inflammatory disorders by administering the composition to a subject in need thereof.

Antibodies targeting VZV glycoprotein E (gE) bind to recombinant gE with high affinity, bind to gE on the surface of VZV infected cells, interact with immune system effectors (e.g., Fc receptors), mediate antibody dependent cytotoxicity (ADCC) and antibody dependent cytophagy (ADCP), and prevent VZV infection of cells.

The invention relates to RIP1 inhibiting compounds and methods of making and using the same. In particular, disclosed herein are kinase inhibitory compounds, such as receptor interacting protein-1 (RIP1) kinase inhibitor compounds, and pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions and / or combinations may be used to treat or prevent kinase-related diseases or disorders, particularly RIP1-related diseases or disorders.

The present invention relates to a compound of formula (I), a pharmaceutical composition containing same, a preparation method therefor, and a use thereof as a receptor-interacting protein kinase 1 (RIPK1) inhibitor. The present invention further relates to a use of the compound or composition containing same for treatment or prevention of related diseases or disorders mediated by RIPK1.

The invention relates to the technical field of nano-materials, in particular to a polypeptide nano-material for binding HER2 and a preparation method and application thereof, the polypeptide nano-material comprises polypeptide with an amino acid sequence as shown in SEQ ID NO: 1 and an I-type photosensitizer connected with the last amino acid of the polypeptide; the polypeptide comprises a ligand unit and a fiber deformation element; the I-type photosensitizer is connected to one end, deviating from the ligand unit, of the fiber deformation element, and the I-type photosensitizer has the aggregation-induced emission characteristic. The polypeptide nano-material can be self-assembled in an aqueous solution through hydrophilic and hydrophobic effects to form spherical nano-particles, the spherical nano-particles are disintegrated through ligand-receptor interaction induction, and an ordered, stable and continuous beta-folding structure is formed through a pi-pi accumulation effect and a hydrogen bond, so that the polypeptide nano-material is converted into a nanofiber network structure in situ in a tumor, and the tumor activity is improved. The type and intensity of active oxygen generated by the I-type photosensitizer with AIE characteristics can be remarkably improved, and finally, specific efficient photodynamic therapy of HER2 positive breast cancer is realized.

The present invention provides a newly identified B7 receptor, zB7R1 that functions as lymphocyte inhibitory receptor, which is a PD-1-like molecule and is expressed on T cells. The present invention also provides the discovery of zB7R1's ability to bind to CD155. Methods and compositions for modulating zB7R1-mediated negative signaling and interfering with the interaction of its counter-receptor for therapeutic, diagnostic and research purposes are also provided.